Le Cochon Noir

51 is a pioneering genomics company dedicated to enhancing the safety and efficacy of gene editing therapies, making transformative therapeutics a safe reality for patients. Their cutting-edge technology, INDUCE-seq, enables the characterization of genome breaks in cell gene therapy applications, providing early access solutions for gene therapy developers to detect edits with high resolution.

With a focus on advancing gene editing safety, 51 has launched several initiatives, including the Catalyst Early Access Program, aimed at expediting the development of gene-edited therapies. The company's collaborations with prominent institutions, like the Francis Crick Institute, further underline its commitment to driving innovation in the field of gene therapy research.

Generated from the website